摘要
目的研究EZH2和P16蛋白在甲状腺癌组织中的表达及意义。方法应用免疫组化SP法对甲状腺乳头癌50例和甲状腺瘤20例进行EZH2和P16检测。结果 EZH2在甲状腺癌的阳性表达率高于甲状腺瘤组织(48.0%与20.0%,P<0.05),P16在甲状腺癌组织中的表达率低于甲状腺瘤组织(42.0%与75.0%,P<0.05),EZH2和P16的表达与转移、复发有关(P<0.05),与性别、年龄、肿瘤大小、临床分期无关(P>0.05)。结论 EZH2和P16可能参与了甲状腺癌的发生和发展,对甲状腺癌的进展监测、预后评估有一定临床应用价值。
Objective To investigate the clinical significance of the expression of EZH2 and P16 protein in thyroid papillary carcinoma. Methods Immunohistochemical staining was used to determine the expression of ezh2 and P16 protein in 50 cases of thyroid papillary carcinoma and 20 cases of adenomas. Results The positive rate of expression of EZH2 in thyroid papillary carcinoma was significantly higher than that of adenomas tussue （ 48% vs 20%,P 0. 05） ,however,the positive rate of expression of P16 in thyroid papillary carcinoma was significantly lower than that of adenomas tussue （ 42. 0% vs 75. 0% ,P 0. 05） . The expression of EZH2 and P16 was closely correlated with metastasis and recurrence （ P 0. 05 ） ,however,there was no correlation with patients’age,sex,tumor size and clinical stage（ P 0. 05） . Conclusion The expression of EZH2 and P16 may be involved in the pathogenesis and development of thyroid carcinoma,which is helpful to monitoring the progression and evaluating prognosis in patients with thyroid carcinoma.
出处
《河北医药》
CAS
2010年第18期2484-2486,共3页
Hebei Medical Journal
